程序性死亡受体配体1、程序性死亡受体1在非小细胞肺癌组织中的表达及临床意义  

Expression and Clinical Significance of Programmed Death-Ligand 1 and Programmed Death-1 in Non-Small Cell Lung Cancer Tissue

作　　者：罗教秀 孙世珺[1] 黄志伟[1] LUO Jiaoxiu;SUN Shijun;HUANG Zhiwei(Department of Pathology,Zhongshan City People's Hospital,Zhongshan Guangdong 528403,China)

机构地区：[1]中山市人民医院病理科,广东中山528403

出　　处：《中国卫生标准管理》2025年第5期113-116,共4页China Health Standard Management

基　　金：2021年度中山市第一批社会公益与基础研究项目(2021B1033)。

摘　　要：目的程序性死亡受体配体1(programmed death-ligand 1,PD-L1)、程序性死亡受体1(programmed death-1,PD-1)在非小细胞肺癌组织中的表达及临床意义,为非小细胞肺癌的防治提供参考。方法选取2022年1月—2023年12月中山市人民医院收治的非小细胞肺癌患者60例为研究对象,收集研究对象的肺癌组织及其癌旁组织,比较不同临床特征非小细胞肺癌组织中PD-1、PD-L1的表达情况。结果TNM为Ⅲ~Ⅳ期、低分化、有淋巴结转移患者的非小细胞肺癌组织中PD-1分别为70.27%、69.44%、85.69%,高于TNM分期为Ⅰ~Ⅱ期、高分化或中分化、无淋巴结转移患者的29.73%、30.56%、14.71%;PD-L1高表达率分别为64.86%、63.89%、79.41%,高于TNM分期为Ⅰ~Ⅱ期、高分化或中分化、无淋巴结转移的患者的35.14%、36.11%、20.59%,差异均有统计学意义(P<0.05)。结论PD-L1、PD-1在非小细胞肺癌组织中高表达,且与疾病分期、分化程度、淋巴结转移等有关,临床上可通过检测PD-L1、PD-1辅助判断病情及预后。Objective To investigate the expression and clinical significance of programmed death-ligand 1(PD-L1)and programmed death-1(PD-1)in non-small cell lung cancer,to provide reference for the prevention and treatment of non-small cell lung cancer tissue.Methods A total of 60 patients with non-small cell lung cancer admitted to Zhongshan City People's Hospital from January 2022 to December 2023 were selected as the study subjects.Both lung cancer tissues and adjacent tissues were collected from the subjects.The expression of PD-1 and PD-L1 in non-small cell lung cancer tissues were compared among patients with different clinical characteristics.Results In non-small cell lung cancer tissues of patients with TNM stageⅠ-Ⅱ,poorly differentiated tumors,or lymph node metastasis,PD-1 expression rates were 70.27%, 69.44% and 85.69% respectively, significantly higher than those in patients with TNM stage Ⅰ-Ⅱ, well/moderately differentiated tumors, or no lymph node metastasis (29.73%, 30.56%, and 14.71%, respectively);PD-L1 showed significantly higher expression rates of 64.86%, 63.89%, and 79.41% respectively, significantly higher than those in patients with TNM stage Ⅰ-Ⅱ, well/moderately differentiated tumors, or no lymph node metastasis (35.14%, 36.11%, and 20.59%, respectively). The differences were statistically significant (P < 0.05). Conclusion PD-L1 and PD-1 are highly expressed in non-small cell lung cancer tissues, and they are related to the stage of the disease, the degree of differentiation and lymph node metastasis. The detection of PD-L1 and PD-1 can help to judge the condition and prognosis in clinic.

关 键 词：非小细胞肺癌 程序性死亡受体配体1 程序性死亡受体1 免疫组织化学染色 肿瘤分期 预后 

分 类 号：R734[医药卫生—肿瘤]